Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
89Zr-rituximab
11%
After Injection
22%
Anti-CD20 Antibody
100%
B Lymphocytes
11%
B-cell Lymphoma
22%
Biodistribution
33%
Burkitt Lymphoma
11%
CD20
22%
Effective Treatment
11%
Fully Human
11%
Human IgG
11%
Human Lymphoma
100%
Humanized
11%
Injected Dose
11%
Monoclonal Antibody
22%
Murine Antibody
11%
Obinutuzumab
77%
Ofatumumab
88%
Palpable Tumor
11%
Peptide Sequencing
11%
Positron Emission Tomography-computed Tomography (PET-CT)
33%
Preclinical Animal Models
11%
Previous Generation
11%
Radioimmunotherapy
44%
Raji
11%
Redosing
22%
Repeated Dosing
11%
Rituximab
44%
Severe Combined Immunodeficient Mice
11%
Small Animal PET
11%
Splenic Uptake
11%
Theranostics
11%
Tositumomab
66%
Tumor
11%
Tumor Targeting
11%
Tumor Uptake
33%
U.S. Food
11%
Xenograft
100%
Zirconium-89 (89Zr)
100%
Medicine and Dentistry
B Lymphocyte Antigen
11%
B-Cell Lymphoma
22%
Biodistribution
33%
Burkitt's Lymphoma
11%
CD20
22%
CD20 Antibody
100%
CT
11%
Effective Treatment
11%
Monoclonal Antibody
22%
Neoplasm
55%
Obinutuzumab
77%
Ofatumumab
88%
Peptide Sequence
11%
Positron Emission Tomography-Computed Tomography
33%
Radioimmunotherapy
44%
Rituximab
66%
SCID Mouse
11%
Tositumomab
66%
Tumor
11%
Xenograft
100%
Zirconium 89
100%
Pharmacology, Toxicology and Pharmaceutical Science
B Cell Lymphoma
22%
B Lymphocyte Antigen
11%
Biodistribution
33%
Burkitt's Lymphoma
11%
CD20 Antibody
100%
Monoclonal Antibody
22%
Mouse Model
11%
Murine
11%
Neoplasm
55%
Obinutuzumab
77%
Ofatumumab
88%
Polyethylene Terephthalate
33%
Rituximab
66%
SCID Mouse
11%
Tositumomab
66%
Zirconium 89
100%
Immunology and Microbiology
Amino Acid Sequence
12%
B Cell
25%
B Lymphocyte Antigen
12%
CD20
25%
CD20 Antibody
100%
Monoclonal Antibody
25%
Mouse Model
12%
Murine
12%
Obinutuzumab
87%
Ofatumumab
100%
Positron Emission Tomography-Computed Tomography
37%
Rituximab
75%
SCID Mouse
12%
Tositumomab
75%
Xenograft
100%